EMR Data to Assess Monitoring of Patients Treated With Quetiapine

Objective Assessment of Metabolic Monitoring in Patients Treated With Seroquel® or Seroquel® XR/Quetiapine Fumarate: Use of IMS Disease Analyzer to Assess Physician Behaviour in the UK and Germany

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01793324

Enrollment

6153

Registered

2013-02-15

Start date

2012-04-30

Completion date

2013-06-30

Last updated

2014-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Major Depressive Disorder, Schizophrenia

Keywords

Effectiveness of risk minimization, Metabolic monitoring, Seroquel® or Seroquel® XR/quetiapine fumarate

Brief summary

A study to evaluate the effectiveness of an update of educational materials with respect to evaluation of monitoring of metabolic parameters

Detailed description

Objective assessment of metabolic monitoring in patients treated with Seroquel® or Seroquel® XR/quetiapine fumarate: use of IMS Disease Analyzer to assess physician behaviour in the UK and Germany

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

\- Electronic medical records of patients with diagnoses of schizophrenia, Bipolar Disorder (BPD) or Major Depressive Disorder (MDD) treated with Seroquel® or Seroquel®XR during the calendar periods: 13 Feb - 31 Aug 2012 seen by GP & psychiatrists in Germany & 11 Jan-31 July 2012 seen by GPs in the UK

Exclusion criteria

\- Patients with above mentioned diagnoses treated with Seroquel® or Seroquel® XR/quetiapine fumarate not having any medical encounters during the time periods: 13 Feb - 31 Aug 2012 in Germany & 11 Jan-31 July 2012 by GPs in the UK

Design outcomes

Primary

Measure	Time frame
Determination whether physicians in the UK and Germany perform monitoring of patients treated with Seroquel® and Seroquel® XR including measurement of the following during patient encounters: weight at drug initiation and over the course of treatment.	Over 6 months following the distribution of metabolic educational materials in the country
Monitoring of hyperlipidemia during patient encounters.	Over 6 months following the distribution of metabolic educational materials in the country
Monitoring for signs and symptoms of hyperglycemia during patient encounters.	Over 6 months following the distribution of metabolic educational materials in the country
Monitoring of blood glucose in patients with diabetes; monitoring of patients with risk factors for diabetes for worsening of glycemic control during patient encounters.	Over 6 months following the distribution of metabolic educational materials in the country
Counseling patients on healthy eating, exercise and healthy lifestyle improvements during patient encounters.	Over 6 months following the distribution of metabolic educational materials in the country

Outcome results